NYMOX PHARMACEUTICAL CORPORATION Proceeds From Exercise Of Warrants
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Proceeds From Exercise Of Warrants of $1.85 million for the 9-month period ending 2024-09-30, per its 6-K filed 2025-01-02.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:ProceedsFromExerciseOfWarrants · last filed 2025-01-02
- NYMOX PHARMACEUTICAL CORPORATION proceeds from exercise of warrants for the quarter ending 2023-09-30 was $1.00M.
- NYMOX PHARMACEUTICAL CORPORATION proceeds from exercise of warrants for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION proceeds from exercise of warrants for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION proceeds from exercise of warrants for the quarter ending 2022-09-30 was $0.00.
| Period end | Proceeds From Exercise Of Warrants 3 month | Proceeds From Exercise Of Warrants 6 month | Proceeds From Exercise Of Warrants 9 month | Proceeds From Exercise Of Warrants 9 month as first filed |
|---|---|---|---|---|
| 2024-09-30 | $1.85M 6-K · filed 2025-01-02 | |||
| 2023-09-30 | $1.00M derived: 6-K 9 month − 6-K 6 month · filed 2025-01-02 | $1.00M derived: sum of 2 quarters · filed 2025-01-02 | $1.00M 6-K · filed 2025-01-02 | $2.00M 6-K · filed 2023-11-15 |
| 2023-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2023-08-14 | $0.00 6-K · filed 2023-08-14 | ||
| 2023-03-31 | $0.00 6-K · filed 2023-05-12 | |||
| 2022-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2023-11-15 | $1.90M derived: sum of 2 quarters · filed 2023-11-15 | $6.01M 6-K · filed 2023-11-15 | |
| 2022-06-30 | $1.90M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-14 | $6.01M 6-K · filed 2023-08-14 | ||
| 2022-03-31 | $4.11M 6-K · filed 2023-05-12 | |||
| 2021-09-30 | $0.00 derived: 6-K/A 9 month − 6-K 6 month · filed 2022-11-16 | $7.28M 6-K/A · filed 2022-11-16 | ||
| 2021-06-30 | $7.28M 6-K · filed 2022-08-15 |